Third Harmonic Bio (THRD)

• Market cap: $155M
• 1 day: -1.71%
• 5 days: -3.90%
• 1 month: 0.58%
• 3 months: -69.36%
• 6 months: -74.58%
• Year to date: -68.75%
• 1 year: -64.21%
• 5 years: -82.47%
• 10 years: -82.47%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Employees: 51

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

95% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 19

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

13% more funds holding

Funds holding: 85 [Q3] → 96 (+11) [Q4]

7.48% less ownership

Funds ownership: 107.16% [Q3] → 99.67% (-7.48%) [Q4]

23% less capital invested

Capital invested by funds: $597M [Q3] → $462M (-$135M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 45% upside
• Avg. target: $5 45% upside
• High target: $5 45% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Morgan Stanley Michael Ulz 26% 1-year accuracy 5 / 19 met price target

45% upside $5

Equal-Weight Downgraded

12 Feb 2025